晚期心力衰竭患者的耐用心室辅助设备:新西兰的经验
Conor W Rea1, Thomas F Pasley2, Peter N Ruygrok3
1Regional Medical Officer, Auckland, New Zealand.
The New Zealand medical journal
|June 20, 2024
概括
在新西兰,左心室辅助器件 (LVAD) 对晚期心力衰竭患者至关重要. 这项研究审查了39名VAD接受者,显示心脏移植后的生存率为62%,突出显示了LVADs.
科学领域:
- 心脏病学 心脏病学
- 医疗技术 医疗技术 医学技术
背景情况:
- 新西兰心力衰竭的患病率越来越高,需要先进的治疗选择.
- 左心室辅助器件 (LVAD) 为某些末期心力衰竭患者提供了至关重要的治疗方法.
研究的目的:
- 为新西兰的临床医生引入持久的机械循环支持 (MCS) 计划,特别是LVAD.
- 突出 LVADs 在管理晚期心力衰竭中的作用和结果.
主要方法:
- 从2005年1月到2022年12月,对心室辅助器件 (VAD) 接受者的回顾性审计.
- 从电子和纸质医疗记录中收集的数据.
- 主要结局:存活到心脏移植或成功的VAD扩展.
主要成果:
- 39名患者接受了VAD; 67%的患者接受了扩张性心肌病.
- 62%的人在心脏移植后存活下来;18%的人在VAD支持下死亡 (原因:RV衰竭,中风).
- 由于康复,一名患者的VAD已经扩展;18%的患者仍在支持中等待移植.
结论:
- 这次审计为新西兰的临床医生提供了关于持久的MCS计划和VADs不断扩大的作用的信息.
- 持续的审计和报告对于高级心力衰竭患者的公平资源分配至关重要.
相关概念视频
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...


